A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

NCT ID: NCT00974129

Last Updated: 2014-06-24

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2012-06-30

Brief Summary

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Detailed Description

This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.

Conditions

Hemangioma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients with Infantile Hemangiomas

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Hemangioma must appear within one month prior to enrollment

Exclusion Criteria

• Hemangioma appeared before one month prior to enrollment

• Maximum Eligible Age: 1 Year
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Yale University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Deepak Narayan, MD

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Yale Dermatology Associates

New Haven, Connecticut, United States

Countries

United States

Other Identifiers

Yale-0430

Identifier Type: -

Identifier Source: secondary_id

0507000430

Identifier Type: -

Identifier Source: org_study_id